IMPORTANCE Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear.
I nfantile hemangioma (IH) is the most common vascular anomaly in children, affecting 10% of all infants in the first year of life. 1 Infantile hemangiomas tend to have a characteristic cycle of growth with 3 distinct phases: proliferation, quiescence, and involution. 2 Although the natural course of IH may be self-limited, it is estimated that up to 40% of lesions will require intervention owing to comorbidity from bleeding, ulceration, disfigurement, obstruction of vision or airway, or high-output cardiac failure. 3 After initial reports [4] [5] [6] [7] [8] of the beneficial effect of propranolol hydrochloride on IH, this β-blocker has quickly become the primary treatment for these vascular tumors. However, the molecular mechanism by which propranolol affects IH remains unclear. A recent review by Ji et al 9 provides a well-organized summary of the leading theories and supportive research. Advances in understanding the details of β-adrenergic signaling have indicated that multiple signaling cascades are affected by β-adrenergic inhibition. Downstream alteration of the expression of endothelial nitric oxide synthase protein and vascular endothelial growth factor has been implicated in the propranolol-induced inhibition of vasculogenesis in IH. 10, 11 Chisholm et al 12 investigated the presence of β 2 -and β 3 -adrenergic receptors (ADBR2 and ADBR3, respectively) as well as phosphorylated ADBR2 via immunohistochemical staining of hemangiomas, hemangioendotheliomas, and various other vascular tumors. The investigators found that ADBR2 and ADBR3 were both present in IH during proliferation and involution. Phosphorylated ADBR2 was present in involuted IH tissue but not during the proliferation phase. According to the authors, the significance of this finding is unknown but was speculated to correlate with the involution process. Also using immunohistochemistry, Boucek et al 13 demonstrated that that β 1 -adrenergic receptor (ADBR1) and ADBR2 were both present in IH pericytes and endothelial cells as well as in congenital hemangiomas, which are typically nonresponsive to propranolol treatment. These findings led to the conclusion that propranolol responsiveness was not determined by a qualitative difference in expression of ADBR. We have sought to further the investigation of β-adrenergic receptors in IH by conducting a quantitative analysis of messenger RNA (mRNA) and protein expression of ADBR1, ADBR2, and ADBR3 for 3 clinical stages of these tumors: proliferation, involution, and response to treatment with propranolol.
Methods
Infantile hemangioma specimens were obtained from the surgical resection of problematic lesions in the proliferative and involution phases of growth as well as from surgical resection of lesions that had been treated with propranolol for 1 month or more. All resections were performed at Arkansas Children's Hospital from 2011 to 2012. 
Western Blot
Total proteins were extracted from approximately 50 mg of tissue using tissue protein extraction reagent (T-PER; Thermo Scientific) added with a protease inhibitor cocktail (Halt Protease Inhibitor Cocktail; Thermo Scientific) and EDTA (1 mM). Protein concentrations were measured using a bicinchoninic acid protein assay kit (Thermo Scientific). Total protein (30 μg) was loaded onto protein gels (NuPAGE Novex 4%-12% BisTris Protein gels; Invitrogen) for electrophoresis under reducing conditions and transferred to polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked with 5% nonfat milk in phosphate-buffered saline and Tween for 1 hour at room temperature, followed by incubation with primary antibodies at 4°C overnight. The primary antibodies used were rabbit antihuman ADBR1 (1:500; Santa Cruz), rabbit antihuman ADBR2 (1:1000; Abcam), goat antihuman ADBR3 (1:500;
Key Points
Question What is the relative β-adrenergic receptor subtype expression profile for infantile hemangioma in proliferation, involution, and response to propranolol treatment?
Findings In this case-control study of 33 specimens of infantile hemangioma, the level of ADBR1 messenger RNA and protein expression was higher in proliferative hemangioma. Protein expression of ADBR3 was greater in involuted and propranolol-responsive hemangiomas.
Meaning These data demonstrate a variable β-adrenergic receptor expression profile for infantile hemangioma in various stages, providing insight into pathogenesis and potential treatment options. Santa Cruz), and rabbit antihuman glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1000; Cell Signaling Technology). Detection of GAPDH was used as the loading control. After washing with phosphate-buffered saline and Tween (Thermo Scientific) 3 times, membranes were reacted with either horseradish peroxidase-conjugated antirabbit or goat secondary antibodies (1:2000; Santa Cruz) for 1 hour at room temperature. Blots were developed (Novex ECL Chemiluminescent Substrate Reagent Kit; Invitrogen) for 1 minute in the dark and exposed on x-ray film (Thermo Scientific). Total protein concentrations were measured by using densitometry with GAPDH as the loading control.
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Statistical Analysis
Statistical analysis for differences in mean amplification (PCR) and protein densitometry (Western blot) was performed with a 2-tailed, unpaired t test, with P < .05 considered statistically significant. The mean values in PCR were normalized against the 18s ribosomal RNA control. GraphPad Software (QuickCalcs 2016; GraphPad Software Inc) was used to calculate means, SDs, and 95% CIs.
Results
A total of 33 specimens were collected from patients who underwent excision of problematic IH. Ten samples were obtained from lesions in the proliferative phase of growth, 11 were from lesions in involution, and 12 were from lesions that had been treated with propranolol and exhibited some response to treatment as indicated by a decrease in size and erythema. Of the 33 patients included, 21 were female (64%). The mean (SD) patient age at the time of excision was 7 (2.5) months, 23.5 (10) months, and 16 (10) months for each of the respective groups (Table) . The head and neck were the most common sites of excision. For patients who were treated with propranolol, the duration of treatment ranged from 1 to 15 months before excision. Five patients (15%) underwent excision after propranolol therapy because of a protuberant fibrofatty residuum, 2 patients (6%) experienced regrowth when attempting to wean from propranolol, 2 patients (6%) experienced continued bleeding and ulceration of the lesion while receiving propranolol, 2 patients (6%) did not tolerate the medication, and 1 patient (3%) with IHs at multiple sites underwent excision of some of the smaller lesions owing to parental preference.
Detection of mRNA Expression Using Real-time PCR
Ten proliferating, 11 involuted, and 12 propranololresponsive IH specimens were used for real-time PCR to detect mRNA expression of each of the subtypes of β-adrener- A, RNA samples from 10 patients with proliferating IH, 11 with involuting IH, and 12 with propranolol-responsive IH were reverse transcripted into complementary DNA and subsequently used for real-time PCR. The messenger RNA expression of the 18s ribosomal RNA was run in parallel as an internal control. The comparative (Ct) method was used to determine relative quantification. The amplification amount of all target genes was normalized against that of 18s ribosomal RNA. The levels of ADBR1 messenger RNA in patients with proliferating IH were significantly higher than in the other 2 groups, but this difference was statistically significant only for propranolol-treated IH. Error bars indicate SD. B, Cycle number data for ADBRs in real-time PCR. Infantile hemangiomas were proliferative in patients 1 to 10, involuted in patients 11 to 21, and propranolol treated in patients 22 to 33. 
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Mean expression levels of ADBR2 mRNA showed no significant differences in the proliferating and involuted groups ( (Figure 1 ). There was no significant amplification of ADBR3 mRNA in any of the 3 groups.
Detection of Protein Expression of β-Adrenergic Receptors Using Western Blot Analysis
Six proliferating, 6 involuted, and 6 propranolol-treated IH specimens were used to detect protein expression of each of the subtypes of β-adrenergic receptors. 
Discussion
To our knowledge, this investigation represents the first to perform real-time PCR and Western blot analysis on IH in 3 different stages of clinical progression: proliferative, involuting, and responsive to propranolol treatment. Protein and mRNA expression levels for ADBR1 and ADBR2 were consistent in each group. However, although ADBR3 protein was detected in involuted and propranolol-treated IH specimens, there was no distinct ADBR3 mRNA expression in any of the groups, a finding similar to that of previous reports. 14 Our results indicate differences between ADBR subtype mRNA and protein expression when comparing proliferative IH with either involuted IH or propranolol-responsive IH. Group comparisons showed that ADBR1 mRNA expression tended to be greater in proliferative IH, suggesting the downregulation of ADBR1 expression as IH progresses into involution, whether by a time-dependent or pharmacologic mechanism. Our findings of a significantly greater amount of ADBR1 expression in proliferating IH compared with treated IH raises the possibility that propranolol's action on ADBR1 is an important component of its molecular mechanism. sion in treatment-responsive and involuted IH is predictable as the tissue transitions from tangled whorls of vascular endothelial cells to a fatty residuum. However, the timing and mechanism by which ADBR3 protein arises in IH tissue remains elusive. Our study sample included patients with a wide range of exposure to propranolol (1-13.5 months). It would perhaps be instructive to analyze tissue at staged resections after the initiation of propranolol therapy to determine whether the expression patterns shift over time.
As a nonselective β-blocker, propranolol has the potential for adverse effects from its blockade of ADBR2. Inhibition of ADBR2 receptors in the liver may result in hypoglycemia through decreased glycogenolysis and gluconeogenesis. 9 In addition, there exists concern for bronchial hyperreactivity due to blockage of pulmonary ADBR2, which may be present in as many as 8% of patients. 4 For this reason, there has been interest in con- have shown little histopathologic difference between responders and nonresponders, demonstrating similar immunohistochemical staining for ADBR1 and ADBR2; however, in these studies, the subtypes were not quantified by mRNA and protein expression. The patients in our study did not include any individuals who failed to show a response to propranolol therapy, but this outcome may be an area of future interest.
Potential limitations to the study include the small sample size, although, to our knowledge, this study represents the largest number of IH samples subjected to PCR and Western blot analysis to date. In addition, because the evolution of IH is age dependent, the molecular changes in the propranololtreated group may be confounded by the fact that 58% of these patients were older than 1 year. However, if only the data from patients younger than 1 year are used, the differences in protein expression remain significant. Another consideration is that 2 patients who experienced regrowth after stopping the medication were included in the propranolol group. It is possible that these patients in effect reverted to a proliferative state in terms of their molecular signature. Finally, an immunohistochemical evaluation of the specimens would be of value to provide insight into which cell types are expressing ADBRs. The pathological endothelial cells of hemangioma tissue would be of primary concern, and it is possible that differing levels of ADBR expression of stromal cells within the samples could affect mRNA and protein expression analysis.
Conclusions
These data demonstrate a difference in the expression of ADBR subtypes in IH between various stages of clinical progression, with indications that ADBR1 is elevated in proliferative lesions but downregulated either by treatment or by the selflimiting nature of IH. In contrast, ADBR3 protein expression, although not mRNA, was elevated in involuting and treatmentresponsive specimens compared with proliferative IH, which is consistent with the evolution to a more fatty tissue type in the involuted and treatment-responsive specimens. These findings may have clinical implications regarding the use of selective vs nonselective β-blockade.
